Gabapentin Solution
Product Images NDC 70518-4445

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 500mg 10ml 70518 4445 01)

Label for Gabapentin Oral Solution, 500 mg/10 mL strength, in a 10 mL quantity. The label indicates the product is repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions specify refrigeration. Manufacturer is Advagen Pharma Limited, Plainsboro, NJ.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin Oral Solution 500 mg/10 mL in a package containing 10 individual 10 mL cups. The label shows it is repackaged by RemedyRepack Inc., Indiana, PA, with storage instructions to keep refrigerated. The label includes NDC 70518-4445 and manufacturer Advagen Pharma Limited, Plainsboro, NJ.*

FDA Label Image

Equation (Gabapentin Oral Solution Figure 01)

An illustration showing the formula for calculating Creatinine Clearance (CLCr). The formula involves age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

Figure 1 (Gabapentin Oral Solution Figure 02)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents time in weeks from baseline, with distinct 4-week dose titration and fixed dose periods, while the y-axis shows mean pain scores ranging from 0 to 10. Gabapentin group scores decrease over time, whereas placebo scores remain relatively stable.*

FDA Label Image

Figure 2 (Gabapentin Oral Solution Figure 03)

A line graph showing mean pain scores over a 7-week period comparing placebo and two doses of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents time in weeks from baseline through a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10.*

FDA Label Image

Figure 3 (Gabapentin Oral Solution Figure 04)

A bar chart comparing efficacy percentages in two studies for gabapentin (GBP) doses versus placebo (PBO). Study 1 shows GBP 3600 at 29% and PBO at 12%. Study 2 presents GBP 1800 at 32%, GBP 2400 at 34%, and PBO at 14%. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gabapentin Oral Solution Figure 05)

A scatter plot chart showing percentage difference on the y-axis and daily dose in milligrams on the x-axis. The chart compares data from three studies labeled as Study a, Study b, and Study c, with Study a in black, Study b in gray, and Study c in white squares. Data points are plotted for doses 600, 900, 1200, and 1800 mg.*

FDA Label Image

Chemical Structure (Gabapentin Oral Solution Structure)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to an amine group (CH2NH2) and an acetic acid moiety (CH2CO2H). This diagram represents the molecular configuration of the active ingredient gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.